Opal-HIV-Gag Clade C vaccine - Opal Therapeutics

Drug Profile

Opal-HIV-Gag Clade C vaccine - Opal Therapeutics

Alternative Names: HIV immunotherapy - Opal Therapeutics/Massachusetts General Hospital; HIV vaccine - Opal Theraputics; Opal-HIV-Gag Clade C; Opal-HIV-Gag(c)

Latest Information Update: 23 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Opal Therapeutics
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 23 Mar 2018 Discontinued - Phase-I for HIV infections in United Kingdom (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections in United Kingdom (Parenteral)
  • 11 Jun 2010 Phase-I clinical trials in HIV infections in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top